Vir Biotechnology, Inc.

ABEJA

Pharmaceuticals, namely, proteins, antibodies, and large molecules for use in the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, immune system related diseases and disorders, and infectious diseases, blood disorders, obesity, and cognitive disorders; none of the foregoing including external use pain reliever preparations, ointments, and liniments;The English translation of ABEJA in the mark is BEE.;Medical research and scientific research information in the field of the production of proteins, antibodies, and large molecules; none of the foregoing relating to external use pain reliever preparations, ointments, and liniments;

VIR

The mark consists of the stylized wording VIR. In the middle of the V is a right triangle.;Color is not claimed as a feature of the mark.;Research and development in the pharmaceutical and biotechnology fields; development of pharmaceutical preparations and medicines;